NanoViricides licenses COVID-19 drug candidates NV-CoV-2 and NV-CoV-2-R to Karveer for India

NANOVIRICIDES, INC.

Exclusive license for development and commercialization in India; Karveer to sponsor Phase I and II clinical trials.
NanoViricides reimburses all direct/indirect trial costs plus a 30% fee; Karveer pays 70% of invoiced commercial sales to NanoViricides.
No minimum royalties or license maintenance fees; term continues as long as Karveer uses NanoViricides' proprietary technologies.
NanoViricides retains full rights to clinical data for use outside India.

item 1.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NANOVIRICIDES, INC. entered into License Agreement with Karveer Meditech Private Limited (effective 2023-03-27).

Action: entry
Agreement: license
Counterparty: Karveer Meditech Private Limited
Effective: 2023-03-27

Exact text from the filing

On March 27, 2023, NanoViricides, Inc. (the “Company”) entered into a License Agreement (the “Agreement”) with Karveer Meditech Private Limited (“Karveer”)

View on SEC.gov

Browse all material agreements →

NANOVIRICIDES, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-040296

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.